June 19, 2008 – Merck KGaA announced today that it has submitted an application to the European Medicines Agency (EMEA) to broaden the use of the targeted therapy Erbitux® (cetuximab) to include first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN).
The submitted label would extend the use of Erbitux for treatment of patients with recurrent and/or metastatic squamous cell cancer of the head and neck in combination with platinum-based chemotherapy.
The details can be read here.
No comments:
Post a Comment